Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.

Marcellin, Patrick

Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. [electronic resource] - Journal of hepatology Jan 2015 - 41-7 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1600-0641

10.1016/j.jhep.2014.08.021 doi


Adult
Antiviral Agents--adverse effects
DNA, Viral--analysis
Drug Carriers
Drug Therapy, Combination
Female
Global Health
Hepatitis B e Antigens--immunology
Hepatitis B virus--genetics
Hepatitis B, Chronic--drug therapy
Humans
Incidence
Interferon-alpha--adverse effects
Male
Peripheral Nervous System Diseases--diagnosis
Polyethylene Glycols--adverse effects
Recombinant Proteins--adverse effects
Telbivudine
Thymidine--adverse effects